Biocryst Pharma Inc (BCRX)

$7.83 -0.02 (-0.25%)
Market Cap 1.51B
Revenue (ttm) 450.71M
Net Income (ttm) -88.88M
EPS (ttm) N/A
PE Ratio 89.50
Forward PE 35.80
Profit Margin -19.72%
Debt to Equity Ratio -1.73
Volume 6,723,400
Avg Vol 5,379,958
Day's Range N/A - N/A
Shares Out 210.54M
Stochastic %K 97%
Beta 0.91
Analysts Strong Sell
Price Target $20.40

Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phas...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 919 859 1302
Fax: 919 859 1314
Address:
4505 Emperor Boulevard, Suite 200, Durham, United States
Smnorgy1
Smnorgy1 Dec. 5 at 2:56 AM
$BCRX Optimist outlook. Oraldeyo , Sprinkles and Astria 1.9 to 2.3 billion. Netherton 450 million. DME, lots more. Total = 2.75 billion to lots more.
0 · Reply
2YrsEarly
2YrsEarly Dec. 5 at 12:41 AM
$BCRX And let’s also be clear on the pediatric revenue opportunity. I’m seeing some crazy numbers being posted. Management has repeated the information below many times on earnings calls/investor conferences. - 500 HAE Pediatric patients in US - Our drug works for roughly 60% of those who try it. - Annual cost of drug is right at $500,000 - So if every kid in the US with HAE tried it then 300 kids would be on he drug. - So absolute max revenue opportunity in the US is 300 kids X $500K = $150M MAX IMO $100M is achievable.
1 · Reply
2YrsEarly
2YrsEarly Dec. 5 at 12:01 AM
$BCRX Shorts do not get burnt on this ticker as there seems to be a large coordinated effort to loan shares, sell short and buy back amongst each other. See Snob’s report below. Just look at what happened last time short interest was this high. (Apr-Jun ‘24) Short interest was cut in half as large dark pool trades covered in the after hours with no price movement and the stock price actually ended up being lower. I expect the same will happen again this time. BS manipulation! Thanks for always sharing this Snob!
1 · Reply
mikesmith2763
mikesmith2763 Dec. 4 at 11:20 PM
$BCRX I just want to remind you that shorts have a lot of skin in trying to keep this under $8.31 and probably added today so don’t be discouraged… the fireworks are coming… this approval will cause a massive headache… charts suggest a new high in the near future 😎 JS
1 · Reply
Iightning
Iightning Dec. 4 at 10:44 PM
1ightning® Premium Options Alert (Actionable) Ticker: $BCRX Contract: Dec 19 $8C Entry: 0.32 Exit: 0.46 Return: +40.91% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Smnorgy1
Smnorgy1 Dec. 4 at 10:19 PM
$BCRX And, this is a bcrx short squeeze, fyi.
1 · Reply
SCCT2FL
SCCT2FL Dec. 4 at 10:13 PM
$BCRX what was the big, but very brief after hours pop to $8.11?
1 · Reply
trustbutverify
trustbutverify Dec. 4 at 9:24 PM
$BCRX “Guidance is go. Trajectory is good. Trim is good. We’re right on the line. All systems are go.”
0 · Reply
SilentEarner
SilentEarner Dec. 4 at 9:05 PM
$BCRX This roller coaster today is a good sign with this volume after yesterday’s move. Liquid stocks making these moves on an upward trajectory generally have much stronger upside to go. Chart boys are salivating
0 · Reply
SCCT2FL
SCCT2FL Dec. 4 at 8:12 PM
$BCRX wrong way!
0 · Reply
Latest News on BCRX
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 4, 2025, 7:00 AM EST - 15 hours ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

Dec 3, 2025, 7:00 AM EST - 1 day ago

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 24, 2025, 2:23 PM EST - 10 days ago

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

BioCryst to Present at Upcoming Investor Conference

Nov 5, 2025, 7:00 AM EST - 4 weeks ago

BioCryst to Present at Upcoming Investor Conference

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 12:16 PM EST - 4 weeks ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 7:00 AM EST - 4 weeks ago

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

Oct 23, 2025, 7:00 AM EDT - 6 weeks ago

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

BioCryst to Report Third Quarter 2025 Financial Results on November 3

Oct 20, 2025, 7:00 AM EDT - 6 weeks ago

BioCryst to Report Third Quarter 2025 Financial Results on November 3

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Oct 17, 2025, 3:20 PM EDT - 6 weeks ago

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

ATXS

BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript

Oct 14, 2025, 1:16 PM EDT - 7 weeks ago

BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

Oct 14, 2025, 12:20 PM EDT - 7 weeks ago

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

ATXS

BioCryst to buy Astria Therapeutics in $700 million deal

Oct 14, 2025, 7:35 AM EDT - 7 weeks ago

BioCryst to buy Astria Therapeutics in $700 million deal

ATXS

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

Oct 14, 2025, 7:00 AM EDT - 7 weeks ago

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

ATXS

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

Oct 1, 2025, 7:00 AM EDT - 2 months ago

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

BioCryst: Blue Light Special In Small Cap Biotech Aisle

Sep 29, 2025, 2:53 AM EDT - 2 months ago

BioCryst: Blue Light Special In Small Cap Biotech Aisle

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 5:47 AM EDT - 3 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 Transcript

BioCryst Announces Departure of Dr. Helen Thackray

Aug 11, 2025, 7:00 AM EDT - 4 months ago

BioCryst Announces Departure of Dr. Helen Thackray

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 11:38 AM EDT - 4 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript

BioCryst (BCRX) Q2 Revenue Jumps 50%

Aug 4, 2025, 7:24 AM EDT - 4 months ago

BioCryst (BCRX) Q2 Revenue Jumps 50%

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 7:00 AM EDT - 4 months ago

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

Jul 31, 2025, 7:00 AM EDT - 4 months ago

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

BioCryst to Report Second Quarter 2025 Financial Results on August 4

Jul 21, 2025, 7:00 AM EDT - 4 months ago

BioCryst to Report Second Quarter 2025 Financial Results on August 4

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

Jul 9, 2025, 7:00 AM EDT - 5 months ago

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

Jul 7, 2025, 7:00 AM EDT - 5 months ago

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Jun 27, 2025, 7:00 AM EDT - 5 months ago

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

Jun 16, 2025, 7:00 AM EDT - 6 months ago

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

ORLADEYO® (berotralstat) Approved in Colombia

Jun 13, 2025, 7:00 AM EDT - 6 months ago

ORLADEYO® (berotralstat) Approved in Colombia

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

Jun 6, 2025, 7:00 AM EDT - 6 months ago

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

Jun 2, 2025, 7:00 AM EDT - 6 months ago

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

May 30, 2025, 7:00 AM EDT - 6 months ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

BioCryst to Present at Upcoming Investor Conferences

May 27, 2025, 7:00 AM EDT - 6 months ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

May 16, 2025, 7:00 AM EDT - 7 months ago

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

May 14, 2025, 7:00 AM EDT - 7 months ago

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

May 5, 2025, 5:29 PM EDT - 7 months ago

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

BioCryst: Strong Opportunity For A Double With A Proven Therapy

May 5, 2025, 2:05 PM EDT - 7 months ago

BioCryst: Strong Opportunity For A Double With A Proven Therapy

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 12:54 PM EDT - 7 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 7:00 AM EDT - 7 months ago

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

BioCryst Appoints Steve Frank to Board of Directors

May 1, 2025, 7:00 AM EDT - 7 months ago

BioCryst Appoints Steve Frank to Board of Directors

BioCryst to Report First Quarter 2025 Financial Results on May 5

Apr 21, 2025, 7:00 AM EDT - 8 months ago

BioCryst to Report First Quarter 2025 Financial Results on May 5

BioCryst: Orladeyo's Expansion Is Just Getting Started

Feb 26, 2025, 9:09 AM EST - 10 months ago

BioCryst: Orladeyo's Expansion Is Just Getting Started

BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up

Feb 26, 2025, 7:45 AM EST - 10 months ago

BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up

BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical

Feb 25, 2025, 6:24 PM EST - 10 months ago

BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical

Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today

Feb 24, 2025, 6:15 PM EST - 10 months ago

Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 12:17 PM EST - 10 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

Feb 24, 2025, 11:49 AM EST - 10 months ago

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

Feb 24, 2025, 7:00 AM EST - 10 months ago

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to

Feb 24, 2025, 6:00 AM EST - 10 months ago

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Feb 12, 2025, 7:00 AM EST - 10 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

Feb 10, 2025, 8:30 AM EST - 10 months ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

Smnorgy1
Smnorgy1 Dec. 5 at 2:56 AM
$BCRX Optimist outlook. Oraldeyo , Sprinkles and Astria 1.9 to 2.3 billion. Netherton 450 million. DME, lots more. Total = 2.75 billion to lots more.
0 · Reply
2YrsEarly
2YrsEarly Dec. 5 at 12:41 AM
$BCRX And let’s also be clear on the pediatric revenue opportunity. I’m seeing some crazy numbers being posted. Management has repeated the information below many times on earnings calls/investor conferences. - 500 HAE Pediatric patients in US - Our drug works for roughly 60% of those who try it. - Annual cost of drug is right at $500,000 - So if every kid in the US with HAE tried it then 300 kids would be on he drug. - So absolute max revenue opportunity in the US is 300 kids X $500K = $150M MAX IMO $100M is achievable.
1 · Reply
2YrsEarly
2YrsEarly Dec. 5 at 12:01 AM
$BCRX Shorts do not get burnt on this ticker as there seems to be a large coordinated effort to loan shares, sell short and buy back amongst each other. See Snob’s report below. Just look at what happened last time short interest was this high. (Apr-Jun ‘24) Short interest was cut in half as large dark pool trades covered in the after hours with no price movement and the stock price actually ended up being lower. I expect the same will happen again this time. BS manipulation! Thanks for always sharing this Snob!
1 · Reply
mikesmith2763
mikesmith2763 Dec. 4 at 11:20 PM
$BCRX I just want to remind you that shorts have a lot of skin in trying to keep this under $8.31 and probably added today so don’t be discouraged… the fireworks are coming… this approval will cause a massive headache… charts suggest a new high in the near future 😎 JS
1 · Reply
Iightning
Iightning Dec. 4 at 10:44 PM
1ightning® Premium Options Alert (Actionable) Ticker: $BCRX Contract: Dec 19 $8C Entry: 0.32 Exit: 0.46 Return: +40.91% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Smnorgy1
Smnorgy1 Dec. 4 at 10:19 PM
$BCRX And, this is a bcrx short squeeze, fyi.
1 · Reply
SCCT2FL
SCCT2FL Dec. 4 at 10:13 PM
$BCRX what was the big, but very brief after hours pop to $8.11?
1 · Reply
trustbutverify
trustbutverify Dec. 4 at 9:24 PM
$BCRX “Guidance is go. Trajectory is good. Trim is good. We’re right on the line. All systems are go.”
0 · Reply
SilentEarner
SilentEarner Dec. 4 at 9:05 PM
$BCRX This roller coaster today is a good sign with this volume after yesterday’s move. Liquid stocks making these moves on an upward trajectory generally have much stronger upside to go. Chart boys are salivating
0 · Reply
SCCT2FL
SCCT2FL Dec. 4 at 8:12 PM
$BCRX wrong way!
0 · Reply
SpencerF
SpencerF Dec. 4 at 8:00 PM
$BCRX are we going to have to do that double bottom crap again? Or is it ever possible to skip doing that?
0 · Reply
ktrader1991
ktrader1991 Dec. 4 at 7:59 PM
$BCRX shorts cover. It’s enough games
0 · Reply
Saffier1988
Saffier1988 Dec. 4 at 7:43 PM
$BCRX classic day.. end low
0 · Reply
Iwillbuy
Iwillbuy Dec. 4 at 7:18 PM
$BCRX Tell me this stock isn’t being controlled by a few tutes here! Working in tandem to try to screw over everyone else here….
0 · Reply
Saffier1988
Saffier1988 Dec. 4 at 7:17 PM
$BCRX its not holding..
2 · Reply
Darryl15
Darryl15 Dec. 4 at 7:00 PM
$BCRX afternoon delight
0 · Reply
YerbMe
YerbMe Dec. 4 at 6:36 PM
$BCRX I love being hyperbolic esp. on a Thursday. 30+ million short shares What could go wrong (on a Friday)?
1 · Reply
knowthyself
knowthyself Dec. 4 at 6:21 PM
$BCRX if I were a short seller, I would bail while they still have a chance. Grok gives it a 80-90% of approval, which could add minimum $300M peak sales to the $1B mark. In addition there is the merger, and the corresponding pipeline. Upon approval, the share price will be over $10, imo.
1 · Reply
BirdStar
BirdStar Dec. 4 at 6:20 PM
$BCRX This is only moving because Fergus sold at $7.
3 · Reply
TheVulcanDevilWhale
TheVulcanDevilWhale Dec. 4 at 6:12 PM
$BCRX greeeeeennnnn🤣
1 · Reply
RonIsWrong
RonIsWrong Dec. 4 at 6:09 PM
$BCRX onwards and ...
2 · Reply
ktrader1991
ktrader1991 Dec. 4 at 6:04 PM
$BCRX go to $15+. We’re undervalued baby
0 · Reply